Business
From the Dark Daily: Infection control teams and clinical laboratory managers may want to look at this new product designed to improve the diagnosis and treatment of sepsis Accurate and fast diagnosis of sepsis for patients arriving in...
PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information...
Debra L. Zynger, MS, MD; Nat Pernick, MD Arch Pathol Lab Med (2023) 147 (11): 1227–1228. https://doi.org/10.5858/arpa.2023-0211-LE To the Editor.—The pathology job market in the United States has been a source of...
Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical’s Pipeline and Accelerate Global...
PathAI: Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costs SECAUCUS, N.J. and BOSTON –...
CHICAGO--(BUSINESS WIRE)--Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration...
